Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

173.25 -3.10 (-1.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,821,353
Open 172.74
Bid (Size) 173.20 (1)
Ask (Size) 173.64 (1)
Prev. Close 176.35
Today's Range 172.40 - 178.74
52wk Range 115.03 - 217.25
Shares Outstanding 387,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 No-Brainer Growth Stocks to Buy in 2023
These stocks all fell by double digits last year. 
Via The Motley Fool
Why Personalis Shares Are Trading Higher Today
 
Via Benzinga

Performance

YTD
-3.21%
-3.21%
1 Month
-0.15%
-0.15%
3 Month
+5.61%
+5.61%
6 Month
-5.30%
-5.30%
1 Year
+6.28%
+6.28%

More News

Read More
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Is Moderna Stock a Buy Now?
Via The Motley Fool
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Via InvestorPlace
Could This RSV News Make Moderna a Hot Buy Again?
Via The Motley Fool
What 10 Analyst Ratings Have To Say About Moderna
Via Benzinga
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
Via ACCESSWIRE
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
Via InvestorPlace
Novavax Shares Jumped in January While Others Slipped
Via MarketBeat
Exposures COVID-19 Product Safety
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Via The Motley Fool
This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now
Via The Motley Fool
Why BioNTech And Moderna Shares Are Falling After Pfizer News
Via Benzinga
Biden Administration Plans To End COVID-19 Public Health Emergency In May
Via Benzinga
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
Via Investor's Business Daily
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Via ACCESSWIRE
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Via The Motley Fool
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
Via Investor's Business Daily
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
How Could GSK's RSV Vaccine Change its Valuation?
Via MarketBeat
Exposures Product Safety
Thursday Predictions: 3 Hot Stocks for Tomorrow
Via InvestorPlace
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.